ArticleTherapeutic advances in hematology2024

Cost-effectiveness of acalabrutinib monotherapy or with obinutuzumab versus chemoimmunotherapy for untreated chronic lymphocytic leukemia in China.

Mengya Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.